Ahmed Z Obeidat

12PUBLICATIONS
49CO-AUTHORS
Medical infection agents (incl. prions)Vision scienceCancer therapy (excl. chemotherapy and radiation therapy)Optical technologyMajor global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 18, 2026
Time-dependent divergence in infection risks among patients with multiple sclerosis treated with fumarates versus anti-CD20 monoclonal antibodies.

|Jul 30, 2026
Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial.

|Apr 16, 2026
Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.

|Feb 18, 2026
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis.

Ahmed Z Obeidat, Michelle Betz, Rebecca Straus Farber

|Feb 10, 2026
Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: The REPLACE-MS study.

Kiranpal Singh Sangha, Collin Jakubecz, Michelle Maynard

|Dec 12, 2025
Satralizumab treatment in adults with aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder in clinical practice.

Hesham Abboud, Brian Steingo, Diana Vargas

Pageof 2

Frequent Collaborators

3 joint publications

Mokshal H Porwal

2 joint publications

Amber Salter

2 joint publications

Sai L Shankar

2 joint publications

Hesham Abboud